CareDx divests Lab Products for $170m as core transplant diagnostics gains momentum
CareDx is selling its Lab Products business for $170 million. Read what the deal means for transplant diagnostics, growth focus, and execution risk.
How Tempus AI and Daiichi Sankyo are using real-world data to reshape antibody-drug conjugate development
Tempus AI and Daiichi Sankyo are using multimodal AI to refine ADC trial strategy and biomarker discovery. Read what this could change next.
BostonGene AI framework identifies actionable targets in 65% of cancer of unknown primary cases at USCAP 2026
BostonGene presents multimodal AI CUP framework at USCAP 2026, identifying actionable targets in 65%+ of patients. Read the analysis.
Dizal’s Zegfrovy challenges chemo dominance in rare EGFR lung cancer mutation
Zegfrovy Phase 3 results could redefine EGFR exon20ins lung cancer treatment. Discover what this means for frontline therapy and future care strategies.
C2N Diagnostics advances PrecivityTauDx programme as tangle biomarker gains Phase 3 evidence
C2N’s eMTBR-tau243 plasma assay shows independent prognostic value in Phase 3 Evoke data. What this means for Alzheimer’s patient selection. Read the analysis.
Fulgent Genetics acquires Bako Diagnostics and StrataDx to expand AI pathology strategy
Fulgent Genetics acquires Bako Diagnostics and StrataDx to scale AI pathology, expand national reach, and advance precision medicine strategy. Read full analysis.
Rhythm Biosciences and datma join forces to validate cancer risk tools with federated data
Rhythm Biosciences Ltd and United States-based federated data platform company datma have announced a strategic exploratory collaboration aimed at validating and scaling genomic-integrated cancer risk prediction through real-world clinical datasets. The partnership centers around the use of datma.FED, a privacy-preserving federated data platform, to evaluate the clinical utility and performance of Rhythm Biosciences’ geneType risk […]
AstraZeneca secures global rights to Jacobio Pharma’s Pan‑KRAS JAB‑23E73 in high‑stakes KRAS market expansion
Find out how Jacobio Pharma’s global licensing deal with AstraZeneca could reshape KRAS‑targeted cancer therapy development.
Wasatch BioLabs, Agilent to scale native-read targeted sequencing for precision multi-omics
Wasatch BioLabs has announced a co-marketing agreement with Agilent Technologies to expand access to its Direct Targeted Methylation Sequencing (dTMS) platform. The partnership integrates Agilent’s SureSelect and Avida enrichment chemistries with Wasatch BioLabs’ Oxford Nanopore-based native-read workflow, aiming to streamline high-throughput targeted sequencing for research use only (RUO) and translational settings. The announcement marks a […]
Why the MiRaDoR study may redefine therapeutic timing in HR+/HER2- patients
Natera Inc. and Medica Scientia Innovation Research (MEDSIR) have announced a collaborative effort on the MiRaDoR study, a multicenter, phase II clinical trial focused on hormone receptor-positive, HER2-negative (HR+/HER2-) breast cancer. Sponsored by MEDSIR and funded by F. Hoffmann-La Roche Ltd., the trial uses Natera’s Signatera assay to guide therapy decisions based on circulating tumor […]